CHRS Coherus Oncology, Inc.
Price Chart
Executive Summary
Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up 60% YoY, driven by increasing patient demand and treatment duration. The company significantly reduced its debt by 90% to $38.8 million and bolstered its cash position to $172.1 million through equity financings, while advancing a promising oncology pipeline with multiple 2026 clinical readouts expected.
Key Financial Metrics
Actionable Insight
Traders should monitor upcoming mid-2026 clinical readouts for tagmokitug and casdozokitug, which could serve as major catalysts. The improved financial position reduces near-term dilution risk, while LOQTORZI's growth trajectory supports potential revaluation if sales continue accelerating.
Key Facts
- LOQTORZI net revenue grew 60% YoY to $42.2 million in 2025, up from $26.4 million in 2024
- Q4 2025 LOQTORZI revenue was $12.4 million, up 64% YoY and 11% QoQ
- Debt reduced from $480 million peak to $38.8 million by end of 2025
- Cash, cash equivalents, and marketable securities totaled $172.1 million as of December 31, 2025
- Company raised $54.9 million in gross proceeds from two equity offerings in late 2025 and early 2026
- Net loss from continuing operations narrowed to $183.1 million in 2025 from $215.4 million in 2024
- Phase 2 data for casdozokitug in uHCC showed 38% ORR and 17% CR rate; multiple 2026 clinical readouts expected
Financial Impact
Revenue increased by $15.8 million YoY; net loss improved by $32.3 million; cash position increased by $46.1 million despite operating losses
Risk Factors
- High cash burn: $138.5 million used in operating activities in 2025
- Significant dilution from recent equity raises: ~33 million new shares issued in 2025-2026
- Pipeline remains early-stage with no guarantees of clinical success
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252311 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.42 awaiting T+5 | awaiting T+5 | — | $1.40 (+1.41%) |
|
May 28, 2026
17d ago
|
DEFA14A
| $1.65 $1.58 | ▼ −4.55% | ▼ −4.86% | $1.40 (−15.15%) |
|
May 11, 2026
4w ago
|
Press Release
| $1.71 $1.49 | ▼ −12.87% | ▼ −12.94% | $1.40 (−18.13%) |
|
May 5, 2026
5w ago
|
DEFA14A
| $1.75 $1.71 | ▼ −2.29% | ▼ −3.42% | $1.40 (−20.00%) |
|
May 4, 2026
5w ago
|
Press Release
| $1.73 $1.95 | ▲ +12.72% | ▲ +9.78% | $1.40 (−19.08%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $1.95 $1.68 | ▼ −13.85% | ▼ −12.94% | $1.40 (−28.21%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $1.65 $1.93 | ▲ +16.97% | ▲ +18.18% | $1.40 (−15.15%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $1.65 $1.93 | ▲ +16.97% | ▲ +18.18% | $1.40 (−15.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access